Home » Topics » Disease categories and therapies » Urology

Urology
RSS

BioSante completes enrollment in phase III safety study of LibiGel

June 1, 2011

GenKyoTex raises funds to develop NADPH oxidase inhibitors

June 1, 2011

RLY-5016 dose titration avoids hypokalemia in patients with heart failure and kidney disease

June 1, 2011

Otsuka Pharmaceutical presents new vasopressin receptor antagonists

May 31, 2011

Primary endpoints met in Vivus' phase III trial of avanafil for ED after radical prostatectomy

May 26, 2011

Scientists at Vantia prepare new kallikrein-1 inhibitors

May 26, 2011

Ampio Pharmaceuticals completes evaluation of phase III data on Zertane

May 25, 2011

TheraVida begins phase II trial of THVD-201

May 20, 2011

Trillium Therapeutics raises funds to advance TTI-1612 into clinical trials

May 13, 2011

Nymox to begin recruitment in new clinical trial of NX-1207

May 12, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...